Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements.
HPTLC
UHPLC-HRMS-MS
adulterants
dietary supplements
sildenafil
tadalafil
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
16 May 2023
16 May 2023
Historique:
received:
20
03
2023
revised:
05
05
2023
accepted:
12
05
2023
medline:
29
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
This study proposed a high-performance thin-layer chromatography (HPTLC) screening method to detect phosphodiesterase 5 (PDE-5) inhibitors as possible adulterant agents in various dietary supplements. Chromatographic analysis was performed on silica gel 60F254 plates using a mixture of ethyl acetate:toluene:methanol:ammonia in a volume ratio of 50:30:20:0.5 as a mobile phase. The system provided compact spots and symmetrical peaks of sildenafil and tadalafil with retardation factor values of 0.55 and 0.90, respectively. The analysis of products purchased from the internet or specialized stores demonstrated the presence of sildenafil, tadalafil, or both compounds in 73.3% of products, highlighting inadequacies and inconsistencies in the labeling, as all dietary supplements were declared to be natural. The results were confirmed using ultra-high-performance liquid chromatography coupled with a positive electrospray ionization high-resolution tandem mass spectrometry (UHPLC-HRMS-MS) method. Furthermore, in some samples, vardenafil and various analogs of PDE-5 inhibitors were detected using a non-target HRMS-MS approach. The results of the quantitative analysis revealed similar findings between the two methods, with adulterant quantities found to be similar to or higher than those in approved medicinal products. This study demonstrated that the HPTLC method is a suitable and economical method for screening PDE-5 inhibitors as adulterants in dietary supplements intended for sexual activity enhancement.
Identifiants
pubmed: 37241857
pii: molecules28104116
doi: 10.3390/molecules28104116
pmc: PMC10221795
pii:
doi:
Substances chimiques
Phosphodiesterase 5 Inhibitors
0
Sildenafil Citrate
BW9B0ZE037
Tadalafil
742SXX0ICT
Cyclic Nucleotide Phosphodiesterases, Type 5
EC 3.1.4.35
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Anal Chem. 2022 Jul 9;2022:3950190
pubmed: 35855809
Br J Clin Pharmacol. 2008 Oct;66(4):444-50
pubmed: 18754850
J Pharm Biomed Anal. 2020 Nov 30;191:113482
pubmed: 32898728
J Pharm Biomed Anal. 2016 Mar 20;121:188-196
pubmed: 26808068
Urology. 2000 Apr;55(4):598-602
pubmed: 10736519
Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2022 Jun;39(6):1021-1032
pubmed: 35323088
Eur Rev Med Pharmacol Sci. 2017 Mar;21(1 Suppl):17-22
pubmed: 28379598
J Pharm Biomed Anal. 2012 Nov;70:40-6
pubmed: 22695818
Molecules. 2014 Jul 03;19(7):9502-14
pubmed: 24995929
Asian J Androl. 2001 Sep;3(3):231-3
pubmed: 11561196
J Sex Med. 2015 Jan;12(1):152-7
pubmed: 25402198
Toxicol In Vitro. 2021 Jun;73:105130
pubmed: 33662516
Asian J Androl. 2006 Sep;8(5):601-5
pubmed: 16751992
J Pharm Biomed Anal. 2014 Jan;87:176-90
pubmed: 23721687
J Androl. 2008 Sep-Oct;29(5):586-91
pubmed: 18421070
Molecules. 2022 Oct 09;27(19):
pubmed: 36235271
Avicenna J Phytomed. 2021 Jul-Aug;11(4):324-331
pubmed: 34290964
Urology. 2015 May;85(5):1214.e7-1214.e15
pubmed: 25772481
J Pharm Biomed Anal. 2011 Dec 5;56(4):705-12
pubmed: 21821375
Ugeskr Laeger. 2020 Jan 20;182(4):
pubmed: 32052735
J Sex Med. 2013 Jul;10(7):1842-9
pubmed: 23634714
Pharmacogn Rev. 2013 Jan;7(13):1-10
pubmed: 23922450
Drug Des Devel Ther. 2018 Dec 18;13:37-43
pubmed: 30587926
Turk J Pharm Sci. 2020 Feb;17(1):56-62
pubmed: 32454761
Andrologia. 2002 Dec;34(6):367-72
pubmed: 12472620
Food Chem. 2019 Aug 1;288:422-443
pubmed: 30902313
Altern Med Rev. 2004 Mar;9(1):4-16
pubmed: 15005641
J Pharm Biomed Anal. 2012 Oct;69:196-208
pubmed: 22464558
J AOAC Int. 2015 Sep-Oct;98(5):1226-33
pubmed: 26525240
Asian J Androl. 2001 Dec;3(4):301-3
pubmed: 11753476
PLoS One. 2015 Apr 28;10(4):e0123547
pubmed: 25919661